SPL-026 is under development for the treatment of major depressive disorder (MDD). The drug candidate is a psychedelic N,N-dimethyltryptamine (DMT) based medicine. It is administered through i ...

In a recent study, transcranial magnetic stimulation was found to be more effective than switching to a new medication for ...

A mental health professional familiar with cognitive remediation would be the best guide for group treatment. Do you live with major depressive disorder? Learn about the resources and protections ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

Depression, which doctors may call major depressive disorder, is a treatable mental ... test to see if you have it and help you manage and treat it. By far, insomnia is the most common sleep ...

What Is TMS? Transcranial magnetic stimulation (TMS) is a treatment FDA-cleared in 2008 for the treatment of Major Depressive ...

Brilaroxazine hydrochloride is under clinical development by Reviva Pharmaceuticals and currently in Phase I for Major Depressive Disorder.

The following is a summary of “Service coverage for major depressive disorder: estimated rates of minimally adequate ...

Vagus nerve stimulation therapy improved the symptoms of treatment-resistant depression for nearly 500 participants in a ...

Neumora Therapeutics to release phase 3 data on Navacaprant for MDD treatment in 2024. Check out NMRA's catalysts that might ...

According to researchers older adults with major depressive disorder (MDD) present with unique and riskier driving behaviors.